Comparison of risks of arterial thromboembolic events and glaucoma with ranibizumab and aflibercept intravitreous injection: A nationwide population-based cohort study.

ABSTRACT:

Background

To compare intravitreal aflibercept injection with intravitreal ranibizumab injection for the risk of major arterial thromboembolic events (ATEs) and glaucoma.

Methods

This retrospective, nationwide cohort study investigated 15 611 and 3867 patients aged >50 years with at least one pharmacy claim for intravitreal ranibizumab injection and aflibercept injection between 2011 and 2016, respectively. The inverse probability of treatment weighting method was performed to adjust the baseline difference between the two groups and the hazard risk of adverse events was estimated using the Cox proportional regression model.

Results

No significant difference was noted between intravitreal ranibizumab and aflibercept injection for arterial thromboembolic risk, includin

SUBMITTER: Chang YH 

PROVIDER: S-EPMC9015139 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature